172@29@17@137!~!172@29@0@53!~!|news|venusremedies|stock-views-VR01-6months.html!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
Moneycontrol
you are here: HomeNewsVenusremedies
stock views
Jump to
13 Results Found
  • Stay invested in Venus Remedies: Prakash Gaba Apr 03, 2017 04:08 PM IST

    Stay invested in Venus Remedies: Prakash Gaba

    Prakash Gaba of prakashgaba.com is of the view that one may stay invested in Venus Remedies.

  • Prefer Granules India, says Gaurang Shah Apr 03, 2017 04:06 PM IST

    Prefer Granules India, says Gaurang Shah

    Gaurang Shah of Geojit Financial Services is of the view that one may prefer Granules India.

  • Top 20 stocks trade at a steep discount to their book value. Should you buy? Apr 03, 2017 08:19 AM IST

    Top 20 stocks trade at a steep discount to their book value. Should you buy?

    Price to book value measure is used for those companies whose present value of the assets cannot be truly reflected in the book value. For banks’ valuation, P/BV is most suited given its borrowing business model and narrow RoE structure.

  • SP Tulsian‘s views on Godrej Cons, Coal India & pvt, PSU banks Jun 02, 2016 09:50 PM IST

    SP Tulsian‘s views on Godrej Cons, Coal India & pvt, PSU banks

    SP Tulsian of sptulsian.com, in an interview to CNBC-TV18, gave his views on various stocks.

  • Your Stocks: Top chart picks by market experts Sep 16, 2014 03:46 PM IST

    Your Stocks: Top chart picks by market experts

    Watch the interview of Vishal Malkan, CMT at malkansview.com and Lancelot D'Cunha, CEO of ITI Wealth Management Pvt Ltd with Reema Tendulkar & Sumaira Abidi on CNBC-TV18, in which they spoke about specific stocks and sectors.

  • Exit Venus Remedies, says Lancelot D'Cunha Sep 16, 2014 03:30 PM IST

    Exit Venus Remedies, says Lancelot D'Cunha

    Lancelot D'Cunha, CEO at ITI Wealth management is of the view that one may exit Venus Remedies.

  • Buy Pidilite, Tata Sponge, Venus Remedies: Manav Chopra Sep 10, 2014 12:59 PM IST

    Buy Pidilite, Tata Sponge, Venus Remedies: Manav Chopra

    Manav Chopra of Nirmal Bang recommends buying Biocon for a target price of Rs 520 and Venus Remedies for a target price of Rs 370.

  • Bull's Eye: Buy Venus Remedies, TNPL; short HDIL, Unitech Sep 10, 2014 08:48 AM IST

    Bull's Eye: Buy Venus Remedies, TNPL; short HDIL, Unitech

    Dharmesh Kant, IndiaNivesh Securities Private Limited advises buying Tamil Nadu Newsprint and Papers for a target price of Rs 172 and Pratibha Industries for a target price of Rs 73.

  • Buy LIC Housing Fin, Yes Bank; sell Tech Mahindra: Cunha Aug 08, 2013 01:51 PM IST

    Buy LIC Housing Fin, Yes Bank; sell Tech Mahindra: Cunha

    Lancelot D Cunha of ITI Wealth Management recommends buying LIC Housing Finance with a target of Rs 172 and advises selling Tech Mahindra August Futures.

  • Bull's Eye: Buy Ceat, Tata Global, YES Bank; sell Tech Mah Aug 08, 2013 08:39 AM IST

    Bull's Eye: Buy Ceat, Tata Global, YES Bank; sell Tech Mah

    Shahina Mukadam of Varun Capital recommended buying Tata Global Beverage with a target price of Rs 152 and Jet Airways with a target price of Rs 352.

  • Tata Motors may slip to Rs 225: Manghnani Aug 10, 2012 10:29 AM IST

    Tata Motors may slip to Rs 225: Manghnani

    Tata Motors may slip to Rs 225, says Anil Manghnani, Modern Shares & Stock Brokers.

  • Bull's Eye: Buy Tata Steel; sell HCL Tech, PFC Jun 19, 2012 12:23 PM IST

    Bull's Eye: Buy Tata Steel; sell HCL Tech, PFC

    Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

  • Venus Remedies may rally to Rs 225, says SP Tulsian May 10, 2012 09:58 AM IST

    Venus Remedies may rally to Rs 225, says SP Tulsian

    Venus Remedies may rally to Rs 225 in a year‘s time, says SP Tulsian, sptulsian.com.

Sections